Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2008 Jan 8;98(1):120–128. doi: 10.1038/sj.bjc.6604134

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2008 Cancer Research UK

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Effect of cetuximab, oxaliplatin, or combination exposure on cell cycle repartition of HCT-8 and HCT-116 cell lines. The cell cycle distribution of HCT-8 and HCT-116 cells was determined after (A) 24 h exposure to drug-free medium (), 20 μg ml⁻¹ cetuximab (C225, ), 5 μM oxaliplatin alone (L-OHP, ), or a combination of both (). (A representative experiment of three independent assessments is shown), and (B) kinetic evolution until 72 h of the percent of cells in G0/G1, S, and G2/M phases after exposure to either vehicle (control), 20 μg ml⁻¹ cetuximab daily (C225), 5 μM oxaliplatin for 24 h followed by drug-free medium (L-OHP), or the combined treatment of oxaliplatin plus cetuximab for 24 h followed by 20 μg ml⁻¹ cetuximab daily (L-OHP+C225). Results are expressed as the mean±s.e.m. of three independent experiments.

Inline graphic — Effect of cetuximab, oxaliplatin, or combination exposure on cell cycle repartition of HCT-8 and HCT-116 cell lines. The cell cycle distribution of HCT-8 and HCT-116 cells was determined after (A) 24 h exposure to drug-free medium (), 20 μg ml⁻¹ cetuximab (C225, ), 5 μM oxaliplatin alone (L-OHP, ), or a combination of both (). (A representative experiment of three independent assessments is shown), and (B) kinetic evolution until 72 h of the percent of cells in G0/G1, S, and G2/M phases after exposure to either vehicle (control), 20 μg ml⁻¹ cetuximab daily (C225), 5 μM oxaliplatin for 24 h followed by drug-free medium (L-OHP), or the combined treatment of oxaliplatin plus cetuximab for 24 h followed by 20 μg ml⁻¹ cetuximab daily (L-OHP+C225). Results are expressed as the mean±s.e.m. of three independent experiments.